Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
266 hedge funds and large institutions have $4.04B invested in Sage Therapeutics in 2019 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 103 increasing their positions, 67 reducing their positions, and 73 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 67
40% more call options, than puts
Call options by funds: $139M | Put options by funds: $99.4M
4.76% less ownership
Funds ownership: 112.84% → 108.08% (-4.8%)
6% less funds holding
Funds holding: 284 → 266 (-18)
14% less first-time investments, than exits
New positions opened: 63 | Existing positions closed: 73
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
51% less capital invested
Capital invested by funds: $8.18B → $4.04B (-$4.14B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$97.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$76.1M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$74.4M |
| 4 |
JP Morgan Chase
New York
|
+$57.3M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$49.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$297M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$223M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$125M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$67.4M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$56.2M |
SAGE Hedge Fund Activity: Q4 2019 in Review
266 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2019, worth a combined $4.04B — down 51% from $8.18B a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of SAGE and 63 opened new positions — a net loss of 10 holders — while 67 trimmed existing stakes and 103 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $97.9M. The largest seller was Jennison Associates, cutting an estimated $297M.
- 266 institutional investors held Sage Therapeutics (SAGE) as of Q4 2019, down from 284 in Q3 2019.
- Funds reported $4.04B of Sage Therapeutics stock for Q4 2019, down 51% quarter-over-quarter.
- 63 funds opened new Sage Therapeutics positions in Q4 2019 and 73 closed out, a net change of -10 holders.
- The largest Sage Therapeutics buyer in Q4 2019 was Great Point Partners, an estimated $97.9M added.
- The largest Sage Therapeutics seller in Q4 2019 was Jennison Associates, an estimated $297M sold.
Based on aggregated 13F filings for Q4 2019.